Weekly Investment Analysts’ Ratings Changes for Rhythm Pharmaceuticals (RYTM)

Several analysts have recently updated their ratings and price targets for Rhythm Pharmaceuticals (NASDAQ: RYTM):

• 6/17/2026 – Rhythm Pharmaceuticals had its “buy” rating reaffirmed by TD Cowen.
• 6/16/2026 – Rhythm Pharmaceuticals had its price target raised by Canaccord Genuity Group Inc. from $143.00 to $151.00. They now have a “buy” rating on the stock.
• 6/15/2026 – Rhythm Pharmaceuticals was given a new $133.00 price target by Stifel Nicolaus.
• 6/15/2026 – Rhythm Pharmaceuticals had its price target raised by Wells Fargo & Company from $144.00 to $155.00. They now have an “overweight” rating on the stock.
• 6/3/2026 – Rhythm Pharmaceuticals had its “market outperform” rating reaffirmed by Citigroup Inc..
• 5/9/2026 – Rhythm Pharmaceuticals was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/7/2026 – Rhythm Pharmaceuticals had its price target raised by Canaccord Genuity Group Inc. from $140.00 to $143.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Rhythm Pharmaceuticals had its price target raised by Royal Bank Of Canada from $136.00 to $137.00. They now have an “outperform” rating on the stock.
• 5/6/2026 – Rhythm Pharmaceuticals had its price target raised by Wells Fargo & Company from $143.00 to $144.00. They now have an “overweight” rating on the stock.

Insiders Place Their Bets

In other Rhythm Pharmaceuticals news, Director Lynn A. Tetrault sold 37,000 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $100.32, for a total value of $3,711,840.00. Following the completion of the sale, the director directly owned 7,000 shares of the company’s stock, valued at $702,240. The trade was a 84.09% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.90% of the stock is owned by insiders.

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.